AbbVie/Shire deal officially off after US thwarts inversion benefits
Jeffrey Clark - Posted: 10/21/2014
For the first time, a company has cancelled its planned merger with a foreign partner for reasons related to tax inversion. After rationalizing its intent by stating obvious synergies between the two companies, AbbVie officials have now announced tha[...]
A challenge for a pharmaceutical company called ISIS
Jeffrey Clark - Posted: 10/17/2014
The editors at CNN asked a very poignant question today, partially relevant to the life sciences industry:  What if your business is called ISIS? Most in the life sciences are aware of ISIS Pharmaceuticals, the drug development firm in Carlsbad, CA l[...]
AbbVie reconsiders Shire deal amid US changes to tax inversions
Jeffrey Clark - Posted: 10/15/2014
Medtronic reaffirmed its commitment last week to acquire Covidien on the heels of the US federal government making it more difficult for companies to benefit from so-called tax inversion deals.  Medtronic believes there is enough strategic synergy to[...]
Chinese firm enters race to develop Ebola treatment
Jeffrey Clark - Posted: 10/14/2014
Ebola is now spreading beyond its stronghold in western Africa to more developed countries.  And, the world is reacting and responding with contingency plans, treatments and potential cures in fast track development. One Chinese drugmaker with close [...]
Becton Dickinson acquires Carefusion for $12B
Jeffrey Clark - Posted: 10/13/2014
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be finalized during the first half of next year.  Recent research and development activities at the two firms have focused on tools used to minimize patient-s[...]
Can Actavis save Allergan from Valeant? And, the Love Quadrilateral?
Jeffrey Clark - Posted: 10/8/2014
Will Actavis ride in as a white knight for Allergan? After being rebuffed by Allergan with a tepid offer last month, Actavis has returned with a more convincing strategy. Actavis is selling the promise of less cost cutting to fund the transaction, wh[...]
Medtronic to finance Covidien deal, avoid appearance of inversion deal
Jeffrey Clark - Posted: 10/7/2014
Medtronic has announced that it will not fund its acquisition of Covidien using foreign cash as it originally planned, but rather will use external financing amounting to $16 billion.   The announcement follows a recent move by the Treasury Departmen[...]
Ebola reaches US, life sciences industry responds
Jeffrey Clark - Posted: 10/2/2014
Ebola has found its way to the United States. The first confirmed US case of Ebola was announced in Dallas this week, from a man who traveled from Liberia (center of the Ebola outbreak in Africa) to Texas. The announcement has health officials scramb[...]
J&J acquires Alios to compete with Gilead and Sovaldi
Jeffrey Clark - Posted: 9/30/2014
Seeing the cash register ring in hepatitis C for Gilead, Johnson & Johnson is making its own move with a $1.75 billion for Alios Biopharma and its development pipeline.   Alios operates in the category of nucleotide analogs (nucs), oral[...]
House votes to repeal medical device tax. But, wait?
Jeffrey Clark - Posted: 9/29/2014
The Republican-controlled House has twice passed legislation to scrap the tax, including a recent measure that would have also delayed implementation of the health law by a year. In the Senate, 33 Democrats and Maine Independent Angus King voted earl[...]
Astellas driving to become Employer of Choice in life sciences
Jeffrey Clark - Posted: 9/25/2014
Ken Jones, CEO of Astellas Pharmaceuticals EMEA, talks about the company's leadership journey as it attempts to evolve as an Employer of Choice across the life sciences industry.
US Treasury clamps down on inversion, big life sciences deals in question
Jeffrey Clark - Posted: 9/23/2014
The U.S. Treasury Department announced steps that will make it harder for US companies to move their addresses outside the country to reduce their taxes, clamping down on the practice known as inversions. The life sciences industry has been at the fo[...]
Salix and Actavis play key roles in Allergan/Valeant saga
Jeffrey Clark - Posted: 9/23/2014
With a looming December 18th special meeting, Allergan and Valeant are playing the chess board. If you believe the press, Actavis recently made a friendly $50B bid for the company which was rejected. And, Allergan is now closing in on its own $10B ac[...]
GSK corruption charges settled in China, suspended jail sentence
Jeffrey Clark - Posted: 9/19/2014
The GSK corruption case in China has come to a conclusion, after a trial that was held in secret. The result is a $489M fine and a suspended sentence for Mark Reilly, GSKs top executive in China.  Reports suggest Reilly will be given a three year sus[...]
What Scotland vote means for life sciences?
Jeffrey Clark - Posted: 9/19/2014
With this mornings announcement that Scotland has rejected a referendum vote for independence, PharmaPhorum has published an article on the immediate and long term positive ramifications for the life sciences industry. Scotland will remain part of th[...]
Israeli robotics company soars with success of ReWalk
Jeffrey Clark - Posted: 9/18/2014
On CNBC this morning, ReWalk CEO Larry Jasinski discusses just how big the market for wearable robotic exoskeleton devices could get. ReWalks have been marketed in Europe since 2012 and received Food and Drug Administration approval for U.S. use in J[...]
Op-ed: High priced drugs are often worth the expense
Jeffrey Clark - Posted: 9/18/2014
Gilead Sciences Sovaldi for hepatitis C is the most successful drug product launch of all time.  It is also an incredibly expensive one-time treatment. And, while the costs of such drugs can hit health care budgets hard all at once, their value to pa[...]
Star Trek meets medical devices with tricorder contest by Qualcomm
Jeffrey Clark - Posted: 9/15/2014
Welcome to the intersection of science fiction and the medical device industry. Qualcomm is sponsoring the Tricorder X contest to create an affordable, handheld device that consumers can use to diagnose their medical conditions at home. The contest’s[...]
Google, Apple, others frustrated by regulatory hurdles for new tech
Jeffrey Clark - Posted: 9/12/2014
This is a fantastic article from the Associated Press on the growing pains felt by Silicon Valley entrepreneurs venturing into the healthcare industry.  Unlike technology where companies can launch a product unabated, companies like Google, Apple and[...]
Third weight loss treatment in past two years approved by FDA
Jeffrey Clark - Posted: 9/11/2014
For the third time in about two years, the Food and Drug Administration has approved a new weight-loss pill.  On Wednesday, FDA released approval to Orexigen Therapeutics oral drug Contrave, for use in chronic weight management along with a low-calor[...]
The next big class of blockbuster drugs?
Jeffrey Clark - Posted: 9/10/2014
Statins are so yesterday. Instead, drug companies are chasing a new class of drugs which aim to lower levels of LDL, or bad cholesterol. This could be a $10 billion market according to Leonard Schleifer, CEO of Regeneron.
To Infinity and beyond: Meet AbbVies newest partner
Jeffrey Clark - Posted: 9/9/2014
Under an agreement announced last week, AbbVie will partner with Infinity Pharma to develop blood cancer treatments. The Cambridge-based company will receive an upfront payment of $275 million and is eligible to receive up to $530 million in addition[...]
Pfizer, Astrazeneca back on?
Jeffrey Clark - Posted: 9/8/2014
There are rumors that Pfizer will again approach AstraZeneca about a takeover. Remember that under UK law, any discussions between Pfizer-AstraZeneca were forced into a cooling off period that began earlier this summer after protracted negotiations f[...]
GSK, others lead the way with expedited Ebola vaccine testing
Jeffrey Clark - Posted: 9/3/2014
GSK has been provided rapid approval by the FDA to start an experimental vaccine against Ebola in humans next week. This is part of a race by the World Health Organization and the National Institutes of Health to deliver a treatment to a rapidly spre[...]
Roche and Intermune CEOs share the spotlight
Jeffrey Clark - Posted: 8/29/2014
Roche CEO Severin Schwan is joined by Intermune CEO Dan Welch to discuss Roches $8.3B acquisition of Intermune in what is the largest deal for Roche since Genentech. Pirfenidone is an orally active, small molecule drug for fibrosis. Pirfenidone is ap[...]
Becton Dickinson acquires[...]
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be final[...]
Ebola reaches US, life sc[...]
Ebola has found its way to the United States. The first confirmed US case of Ebola was announced in [...]
Astellas driving to becom[...]
Ken Jones, CEO of Astellas Pharmaceuticals EMEA, talks about the company’s leadership journey as it [...]
US Treasury clamps down o[...]
The U.S. Treasury Department announced steps that will make it harder for US companies to move their[...]
Israeli robotics company [...]
On CNBC this morning, ReWalk CEO Larry Jasinski discusses just how big the market for wearable robot[...]